Cite
Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma.
MLA
Poh, Han Ming, et al. “Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma.” Cancers, vol. 11, no. 10, Oct. 2019, p. 1528. EBSCOhost, https://doi.org/10.3390/cancers11101528.
APA
Poh, H. M., Chiou, Y. S., Chong, Q. Y., Chen, R.-M., Rangappa, K. S., Ma, L., Zhu, T., Kumar, A. P., Pandey, V., Basappa, Lee, S.-C., & Lobie, P. E. (2019). Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma. Cancers, 11(10), 1528. https://doi.org/10.3390/cancers11101528
Chicago
Poh, Han Ming, Yi Shiou Chiou, Qing Yun Chong, Ru-Mei Chen, Kanchugarakoppal S. Rangappa, Lan Ma, Tao Zhu, et al. 2019. “Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma.” Cancers 11 (10): 1528. doi:10.3390/cancers11101528.